•
CA
CADL
Candel Therapeutics, Inc. Common Stock
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
325.00M
Volume
715.64K
52W High
$13.68
52W Low
$4.25
Open
$6.05
Prev Close
$5.92
Day Range
5.97 - 6.35
About Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Latest News
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
GlobeNewswire Inc.•Nov 4
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
GlobeNewswire Inc.•Apr 1
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
GlobeNewswire Inc.•Mar 18
Candel Therapeutics Announces $80 Million Proposed Public Offering
GlobeNewswire Inc.•Dec 12
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
GlobeNewswire Inc.•Sep 4
Candel Therapeutics executive sells over $63k in company stock - Investing.com
Investing.com•Jul 19
Candel Therapeutics to Join Russell 3000® Index
GlobeNewswire Inc.•Jun 11
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Zacks Investment Research•May 28